Q: Good morning,
Knowing you do not cover US stocks, what are your thoughts on the company slashing their forward profit and revenue forecast and its sales miss (3rd quarter in a row).
Would this be a good entry point or is it a catching a falling knife. Realizing the biotech sector is a risky one, but Biogen seems to have little debt and it is well diversified.
Thank you.
Elaine
Knowing you do not cover US stocks, what are your thoughts on the company slashing their forward profit and revenue forecast and its sales miss (3rd quarter in a row).
Would this be a good entry point or is it a catching a falling knife. Realizing the biotech sector is a risky one, but Biogen seems to have little debt and it is well diversified.
Thank you.
Elaine